Ardelyx, Inc.
corporate_fare Company Profile
Ardelyx, Inc. (NASDAQ:ARDX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for ARDX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for ARDX spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Ardelyx 10-Q: Q3 Revenue $127.7M, Net Loss $0.7M, $285.3M Cash, New Securities Suit Disclosed
- Ardelyx Q3 Product Revenue $125.5M, Net Loss Narrows to $0.7M; Guidance Reiterated
- Ardelyx Posts $127.7M in Q3 Revenue, Topping Last Quarter's Record
- Ardelyx Chief Commercial Officer Resigns Effective August 28
- Ardelyx Slashes IBSRELA Guidance by $60M Despite Record Q2 Revenue
Financial Snapshot
Short Interest & Short Volume
7.53 days to coverFINRA reported short interest of 29,205,209 shares in ARDX as of the October 30, 2026 settlement, a 3.4% decrease from the prior period — about 7.5 days to cover at its recent average daily volume. On November 20, 2026, 46.1% of ARDX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ARDX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-17.
Equity Plan Share Increase Approved · Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →